Welcome!

.NET Authors: Adine Deford, Srinivasan Sundara Rajan, David Fletcher, Pat Romanski, Tad Anderson

News Feed Item

El grupo Galés AWMSG y el Consorcio Escocés de Medicamentos aceptan el uso de la nueva presentación bebible y apta para niños de Inovelon® (rufinamida)

HATFIELD, Inglaterra, November 6, 2012 /PRNewswire/ --

Esta nueva opción ofrece posibilidades de elección para los niños y jóvenes con síndrome de Lennox-Gastautuna forma grave de epilepsia

El grupo AWMSG (All Wales Medicines Strategy Group) y el Consorcio Escocés de Medicamentos (SMC) han aceptado el uso de Inovelon® (rufinamida) en suspensión oral en Gales y Escocia respectivamente, para el tratamiento coadyuvante de las crisis relacionadas con el síndrome de Lennox-Gastaut (SLG), una forma de epilepsia muy debilitante, en niños a partir de cuatro años. El AWMSG y el SMC ha limitado su uso a pacientes en los que haya fracasado el tratamiento con otros fármacos antiepilépticos o muestren intolerancia a los mismos.[1],[2]

La decisión del AWMSG y el SMC de aceptar el uso de la suspensión oral de rufinamida es posterior a su aprobación de la formulación de comprimidos en 2008, sustentada en datos que indican que es capaz de reducir la frecuencia de las crisis totales y las tónicas/atónicas de forma significativa, además de reducir la gravedad de las crisis de forma significativa, en comparación con placebo en pacientes con SLG.[3] La suspensión oral ha demostrado su bioequivalencia y supone un impacto presupuestario mínimo en Gales y Escocia, por lo que ha sido aprobada siguiendo un procedimiento abreviado. Muchos de los pacientes tratados con rufinamida, un medicamento huérfano, son niños. Esta nueva presentación apta para niños, líquida, bebible y con sabor naranja se ha desarrollado para facilitar la administración del tratamiento

«Como a algunos niños les resulta difícil tragar los comprimidos convencionales, existe una gran necesidad de medicinas bebibles, en especial al tratar a pacientes jóvenes de SLG», explica Helen Cross, Directora de la Unidad de Neurociencia del University College London, Instituto de Salud Infantil. «El acceso a la formulación de suspensión de rufinamida puede ayudar a los jóvenes a seguir mejor el tratamiento, lo que permitirá obtener mejores resultados en el tratamiento de esta enfermedad grave y muy debilitante».

El SLG es una forma de epilepsia poco frecuente pero grave que representa un cinco por ciento de todos los casos y supone aproximadamente el 10 por ciento de los casos de epilepsia infantil.[4] La incidencia anual de la enfermedad afecta a aproximadamente 2,8 de cada 10.000 nacimientos en Europa.[4] El seguimiento del tratamiento es vital para el correcto manejo del SLG en los niños, ya que la enfermedad se caracteriza por numerosas crisis diarias, retraso mental y regresión.[5]

«La aprobación del AWMSG y el SMC de la nueva presentación líquida de rufinamida es importante, ya que permitirá abordar las necesidades de seguimiento de los niños y jóvenes con esta forma grave de epilepsia», afirma Mike Bee, director de la unidad de negocio de epilepsia para el norte de la UE. «Estas aprobaciones están en línea con nuestro compromiso continuo con el área terapéutica de la epilepsia y ejemplifica nuestro objetivo de aumentar los beneficios que ofrecen nuestras medicinas a los pacientes y sus familias a través de la misión de  Eisai con el cuidado de la salud humana (hhc por sus siglas en inglés)».

La dosis de la suspensión oral es equivalente en miligramos a los comprimidos de rufinamida comercializados actualmente. La aprobación del AWSMG y el SMC para el uso de la suspensión oral se produce después de su comercialización en Inglaterra, los Países Bajos y Alemania. La nueva formulación se presentará en otros países europeos este mismo año.

La rufinamida en suspensión oral recibió la opinión positiva del CHMP en septiembre de 2011 y obtuvo la aprobación formal de la EMA en noviembre de 2011. El medicamento fue aprobado por la FDA y se comercializó en los Estados Unidos en marzo de 2011 (la rufinamida se comercializa como BANZEL® en los Estados Unidos).  

Acerca de Inovelon® (rufinamida)

La rufinamida es un derivado de triazol que carece de relación estructural con los fármacos antiepilépticos (FAE) que se comercializan actualmente. Se cree que regula la actividad de los canales de sodio del cerebro que transmiten cargas eléctricas excesivas. El agente se aprobó como terapia coadyuvante para el SLG en Europa (con el nombre comercial de Inovelon) en 2007.[2] Inovelon está disponible en forma de comprimidos recubiertos que contienen 100 mg, 200 mg y 400 mg de rufinamida.

La formulación de rufinamida en comprimidos recubiertos se comercializó por primera vez en Europa en mayo de 2007 y actualmente está disponible en 19 países europeos.

Acerca del síndrome de Lennox-Gastaut

El SLG es una forma debilitante de epilepsia de inicio infantil que aparece con mayor frecuencia entre las edades de dos a siete años. Se caracteriza por crisis frecuentes y de múltiples tipos y suele ir acompañada de retraso mental y problemas psicológicos y de comportamiento.[6]

Acerca de la epilepsia

La epilepsia es uno de los trastornos neurológicos más comunes del mundo, que afecta aproximadamente a 8 de cada 1.000 personas en Europa y se estima que hay 50 millones de personas con este trastorno en todo el mundo, 10,5 millones de las cuales son niños menores de 15 años.[7],[8],[9] En Escocia, este trastorno afecta a casi 40.000 personas.[10]

La epilepsia se caracteriza por la generación anormal de impulsos desde las células nerviosas del cerebro que causan las crisis. Según el tipo, las crisis pueden limitarse a una parte del cerebro (parciales) o pueden ser generalizadas cuando le afectan en su totalidad.

Los pacientes también pueden experimentar sensaciones anormales, alteraciones del comportamiento o alteraciones de la consciencia. La epilepsia es un trastorno que tiene muchas causas posibles. Con frecuencia estas causas son desconocidas. Sin embargo, cualquier factor que altere la actividad normal de las neuronas, desde una enfermedad hasta daños cerebrales o tumores, puede producir una crisis.[11]

Acerca de Eisai Europa en relación con la epilepsia

Eisai está comprometida con el desarrollo y el suministro de nuevos tratamientos beneficiosos para ayudar a mejorar las vidas de las personas con epilepsia. El desarrollo de FAE es una importante área estratégica para Eisai en Europa, Oriente Medio, África y Rusia (EMEA).

En Europa, Eisai comercializa actualmente cuatro medicamentos:

  • Zonegran® (zonisamida) como monoterapia y tratamiento coadyuvante en pacientes adultos con crisis de inicio parcial con generalización secundaria o sin ella. (Zonegran está bajo licencia de Dainippon Sumitomo Pharma)
  • Zebinix® (acetato de eslicarbazepina) como tratamiento adyuvante en pacientes adultos con crisis de inicio parcial, con o sin generalización secundaria. En España, el representante local del laboratorio titular de la autorización de comercialización de Zebinix® en la Unión Europea es Bial Industrial Farmacéutica, S.A.
  • Inovelon® (rufinamida) para el tratamiento adyuvante en pacientes de 4 y más años de crisis asociadas con el síndrome de Lennox-Gastaut.
  • Fycompa® (perampanel) como tratamiento coadyuvante para las crisis de inicio parcial, con crisis secundarias generalizadas o sin ellas, en pacientes con epilepsia mayores de 12.

Acerca de Eisai

Eisai ha ampliado recientemente sus instalaciones comerciales, de investigación y producción en Hatfield, Reino Unido, que ahora respaldan el crecimiento del negocio de la empresa en EMEA.

Eisai concentra sus actividades de I+D en tres áreas fundamentales:

  • Área de Neurociencias, que incluye enfermedad de Alzheimer, dolor neuropático, epilepsia, dolor y pérdida de peso.
  • Área de Oncología: tratamientos contra el cáncer; regresión tumoral, supresión tumoral, anticuerpos, etc.
  • Vascular / respuesta inmunológica, incluyendo trombocitopenia, artritis reumatoide, psoriasis, enfermedad inflamatoria intestinal.

Con filiales en los Estados Unidos, Asia, Europa y Japón, Eisai tiene más de 11.000 empleados en todo el mundo. En Europa, Eisai tiene filiales comerciales en más de 20 países que incluyen el Reino Unido, Francia, Alemania, Italia, España, Suiza, Suecia, Irlanda, Austria, Dinamarca, Finlandia, Noruega, Portugal, Islandia, República Checa, Eslovaquia, Países Bajos y Bélgica.

Si desea más información visite nuestro sitio web http://www.eisai.com

Bibliografía

1.  Scottish Medicines Consortium. Inovelon product update. http://www.scottishmedicines.org.uk/files/advice/rufinamide_Inovelon_ABBREVIATED_June_2012_for_website.pdf. Last accessed 3 September 2012

2.  All Wales Strategic Medicines Group. Inovelon product update. http://www.wales.nhs.uk/sites3/Documents/371/rufinamide%20%28Inovelon%29%20FAR.pdf
Last accessed 2 November 2012

3.  Inovelon tablets Summary of Product Characteristics http://www.medicines.org.uk/emc/medicine/20165/SPC/ (Accessed January 2012)

4.  Kenou van Rijckevorsel Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008 December; 4(6): 1001-1019.

5.  MedScape references Lennox-Gastaut Syndrome http://emedicine.medscape.com/article/1176735-overview (Accessed February 2012)

6.  International Journal of Pharma and Bio Sciences. http://www.ijpbs.net/issue-3/82.pdf (Accessed February 2012)

7.  Forsgren L. Epilepsy in Children. 2nd Ed London. Arnold, 2004. 21-25

8.  Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224-2233

9.  Epilepsy Society UK: http://www.epilepsysociety.org.uk/AboutEpilepsy/Whatisepilepsy/Epilepsy-didyouknow (Accessed February 2012)

10. Epilepsy Scotland available at: http://www.epilepsyscotland.org.uk/ (Accessed 01 November 2010). 11.     Epilepsy Research UK. What is Epilepsy? Fact sheet. Available from URL: http://www.epilepsyresearch.org.uk/about_us/leaflets/lflt1.htm (Accessed February 2012)

11. Epilepsy Research UK. What is Epilepsy? Fact sheet. Available from URL: http://www.epilepsyresearch.org.uk/about_us/leaflets/lflt1.htm (Accessed February 2012)

Fecha de preparación: noviembre de 2012
Código de trabajo: Inovelon-UK2271

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
SYS-CON Events announced today that IDenticard will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. IDenticard™ is the security division of Brady Corp (NYSE: BRC), a $1.5 billion manufacturer of identification products. We have small-company values with the strength and stability of a major corporation. IDenticard offers local sales, support and service to our customers across the United States and Canada. Our partner network encompasses some 300 of the world's leading systems integrators and security s...
The BPM world is going through some evolution or changes where traditional business process management solutions really have nowhere to go in terms of development of the road map. In this demo at 15th Cloud Expo, Kyle Hansen, Director of Professional Services at AgilePoint, shows AgilePoint’s unique approach to dealing with this market circumstance by developing a rapid application composition or development framework.
“In the past year we've seen a lot of stabilization of WebRTC. You can now use it in production with a far greater degree of certainty. A lot of the real developments in the past year have been in things like the data channel, which will enable a whole new type of application," explained Peter Dunkley, Technical Director at Acision, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com), moderated by Ashar Baig, Research Director, Cloud, at Gigaom Research, Nate Gordon, Director of T...
"BSQUARE is in the business of selling software solutions for smart connected devices. It's obvious that IoT has moved from being a technology to being a fundamental part of business, and in the last 18 months people have said let's figure out how to do it and let's put some focus on it, " explained Dave Wagstaff, VP & Chief Architect, at BSQUARE Corporation, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Windstream, a leading provider of advanced network and cloud communications, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Windstream (Nasdaq: WIN), a FORTUNE 500 and S&P 500 company, is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, phone and digital TV services to consumers primarily in rural areas.
The Internet of Things is not new. Historically, smart businesses have used its basic concept of leveraging data to drive better decision making and have capitalized on those insights to realize additional revenue opportunities. So, what has changed to make the Internet of Things one of the hottest topics in tech? In his session at @ThingsExpo, Chris Gray, Director, Embedded and Internet of Things, discussed the underlying factors that are driving the economics of intelligent systems. Discover how hardware commoditization, the ubiquitous nature of connectivity, and the emergence of Big Data a...

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's platform-as-a-service. The new platform enables developers to build ap...

DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential.
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Nigeria has the largest economy in Africa, at more than US$500 billion, and ranks 23rd in the world. A recent re-evaluation of Nigeria's true economic size doubled the previous estimate, and brought it well ahead of South Africa, which is a member (unlike Nigeria) of the G20 club for political as well as economic reasons. Nigeria's economy can be said to be quite diverse from one point of view, but heavily dependent on oil and gas at the same time. Oil and natural gas account for about 15% of Nigera's overall economy, but traditionally represent more than 90% of the country's exports and as...
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker. The mesh of things that we manage must be segmented into zones of trust for sensing data, transmitting data, receiving command and control administrative changes, and peer-to-peer mesh messaging. In his session at @ThingsExpo, Ryan Bagnulo, Solution Architect / Software Engineer at SOA Software, focused on desi...
"At our booth we are showing how to provide trust in the Internet of Things. Trust is where everything starts to become secure and trustworthy. Now with the scaling of the Internet of Things it becomes an interesting question – I've heard numbers from 200 billion devices next year up to a trillion in the next 10 to 15 years," explained Johannes Lintzen, Vice President of Sales at Utimaco, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"For over 25 years we have been working with a lot of enterprise customers and we have seen how companies create applications. And now that we have moved to cloud computing, mobile, social and the Internet of Things, we see that the market needs a new way of creating applications," stated Jesse Shiah, CEO, President and Co-Founder of AgilePoint Inc., in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the industry’s first all flash version of HyperConverged Appliances that include both compute and storag...
Today’s enterprise is being driven by disruptive competitive and human capital requirements to provide enterprise application access through not only desktops, but also mobile devices. To retrofit existing programs across all these devices using traditional programming methods is very costly and time consuming – often prohibitively so. In his session at @ThingsExpo, Jesse Shiah, CEO, President, and Co-Founder of AgilePoint Inc., discussed how you can create applications that run on all mobile devices as well as laptops and desktops using a visual drag-and-drop application – and eForms-buildi...
We certainly live in interesting technological times. And no more interesting than the current competing IoT standards for connectivity. Various standards bodies, approaches, and ecosystems are vying for mindshare and positioning for a competitive edge. It is clear that when the dust settles, we will have new protocols, evolved protocols, that will change the way we interact with devices and infrastructure. We will also have evolved web protocols, like HTTP/2, that will be changing the very core of our infrastructures. At the same time, we have old approaches made new again like micro-services...
Code Halos - aka "digital fingerprints" - are the key organizing principle to understand a) how dumb things become smart and b) how to monetize this dynamic. In his session at @ThingsExpo, Robert Brown, AVP, Center for the Future of Work at Cognizant Technology Solutions, outlined research, analysis and recommendations from his recently published book on this phenomena on the way leading edge organizations like GE and Disney are unlocking the Internet of Things opportunity and what steps your organization should be taking to position itself for the next platform of digital competition.
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
As the Internet of Things unfolds, mobile and wearable devices are blurring the line between physical and digital, integrating ever more closely with our interests, our routines, our daily lives. Contextual computing and smart, sensor-equipped spaces bring the potential to walk through a world that recognizes us and responds accordingly. We become continuous transmitters and receivers of data. In his session at @ThingsExpo, Andrew Bolwell, Director of Innovation for HP's Printing and Personal Systems Group, discussed how key attributes of mobile technology – touch input, sensors, social, and ...